Dr. Michael S. Leapman

James McKiernan, MD, is the John K. Lattimer Professor of Urology and CEO of ColumbiaDoctors. He is also Senior Vice Dean for Clinical Affairs for Columbia University Vagelos College of Physicians and Surgeons. Dr. McKiernan graduated from Johns Hopkins University with a BA in biology and received his MD from Columbia University College of Physicians and Surgeons. He completed his training in urology and general surgery at NewYork-Presbyterian Hospital, followed by a urologic surgical oncology fellowship at Memorial Sloan-Kettering Cancer Center. Dr. McKiernan's clinical practice is focused on urologic oncology and particularly on surgical therapy in high-risk patients with bladder and kidney cancers. Dr. McKiernan evaluates and treats over 1,000 patients with bladder cancer every year. His research, funded by NIH and biotechnology industry grants, focuses on developing novel therapeutics for bladder cancer treatment as well as comparative effectiveness research in urologic oncology. In the management of kidney and bladder cancer, he has special expertise in organ preservation and reconstructive surgery to maximize quality of life. Dr. McKiernan's research has been published in Cancer, Cancer Research, the Journal of Clinical Oncology, JAMA Oncology, Journal of Urology, Urologic Oncology, and Urology. He has authored and co-authored more than 220 scientific articles and book chapters on urologic cancer and related issues.For the past 10 years, he has directed a research team at Columbia University Medical Center investigating quality outcomes and effectiveness in urologic cancer surgery. He has served as the Vice Chairman for the AJCC TNM Staging Task Force, Co-Chair of the AUA Guidelines Panel on non-muscle invasive bladder cancer, as well as on the American Board of Urology and Society of Urologic Oncology Examination Committees. In addition, Dr. McKiernan is the principal investigator of the NIH-funded clinical trials program of experimental therapeutics in bladder cancer at Columbia University/NYPH, which is investigating new agents for bladder preservation in patients whose cancer has recurred after standard therapy. In collaboration with researchers at Columbia's Herbert Irving Comprehensive Cancer Center, his team continues to develop new therapeutic strategies for managing bladder cancer. Dr. Mckiernan is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Muscle Invasive Bladder Cancer, Urothelial Cancer, Cystectomy, and Nephrectomy. Dr. Mckiernan is board certified in Urology. Dr. Mckiernan is currently accepting new patients.

Patrick Kenney is a Urologist practicing medicine in New Haven, Connecticut. Dr. Kenney is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Bladder Cancer, Muscle Invasive Bladder Cancer, Nephrectomy, and Reconstructive Urology Surgery.

As Senior Vice President of the Urology Service Line, Chair of theSmith Institute for Urology, and Chair of Urology at the Zucker Schoolof Medicine at Hofstra/Northwell, Samir Taneja, MD will establish hisclinical practice at Lenox Hill Hospital and Long Island Jewish MedicalCenter focused on the surgical management of prostate cancerand renal tumors. He is an expert in urologic oncology, renowned fortransforming the field of prostate cancer diagnosis and treatmentby improving methods of prostate imaging, cancer detection, anddisease localization. Having performed thousands of robotic, ablative,laparoscopic and open surgical procedures, his specific clinical focushas been in improving prostate cancer patient outcomes throughpioneering techniques for focal ablative therapy, refining surgicaltechniques for robotic prostatectomy and partial nephrectomy,devising accelerated recovery pathways for robotic prostatectomy/partial nephrectomy, and providing muti-modal surgical approachesfor patients with high risk and recurrent prostate cancer. As leader ofthe department, he will strive to ensure individualized care of urologicdisease through state-of-the-art surgical approaches and multi-disciplinary care.Prior to joining Northwell, Dr Taneja was a faculty member of NYUGrossman School of Medicine for 29-years as a tenured professorof urology, radiology, and biomedical engineering. Most recently heserved as Director of the Division of Urologic Oncology and ViceChair in the Department of Urology at NYU Langone Health, as well asGenitourinary Program Leader in the Perlmutter Cancer Center.Dr. Taneja has conducted extensive clinical research on the use ofimaging in prostate cancer and is considered a pioneer in the use ofMRI to diagnose and localize prostate cancer and the emerging field ofprostate cancer focal therapy. He has authored more than 250 articles,30 book chapters, and six textbooks and monographs on urologiccancer and surgery. He is the editor of Taneja's Complications ofUrologic Surgery: Prevention and Diagnosis, one of the most widely readtextbooks in American Urology. Dr. Taneja is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Prostatectomy, and Nephrectomy. Dr. Taneja is board certified in American Board Of Urology. Dr. Taneja is currently accepting new patients.